메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
한국병원약사회 병원약사회지 병원약사회지 제37권 제1호
발행연도
2020.1
수록면
11 - 19 (9page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background : Multidrug resistant (MDR) Acinetobacter baumannii (A. baumannii) and Pseudomonas aeruginosa (P. aeruginosa) have emerged as major pathogens of pneumonia in the intensive care unit (ICU). Colistin is used as a drug of choice against pneumonia caused by these pathogens, but when it is administrated systemically, adverse effects such as renal toxicity and neurotoxicity limit its application. Recently, nebulized treatment of colistin has been widely applied to reduce these adverse effects, but the clinical data of nebulized colistin has been limited. The purpose of this study was to compare the efficacy and safety of nebulized colistin with intravenous colistin. Methods : A retrospective medical records review was conducted on patients admitted to the ICUs at a teaching hospital. The patients were diagnosed with pneumonia caused by MDR A. baumanniior P. aeruginosa and treated with colistin either by intravascular or nebulized form August 2015-July 2016. Results : This study included 88 patients, of whom 29 received intravenous colisitin (IV group), and 59 nebulized colistin (Neb group). The mean duration of treatment was 14.8 days in the IV group and 15.8 days in the Neb group (p=0.604). The success rate of treatment based on clinical response and negative conversion rate were not different between the two groups (58.6% vs. 54.2%, OR 0.84, 95% CI 0.34-2.06, p=0.697, respectively). The number of patients whose white blood cell count recovered to normal range during or after colistin treatment was significantly larger in the Neb group than the IV group (55.9% vs. 41.4%, OR 3.77, 95% CI 1.55-9.15, P=0.003, respectively). The negative conversion rate was not different between the two groups (41.4% vs. 37.3%, OR 0.84, 95% CI 0.34- 2.09, p=0.711, respectively). The serum creatinine difference before and after the colistin treatment was significantly greater in the IV group than in the Neb group (0.48±0.17 vs. 0.01±0.11, p=0.016). The acute kidney injury (AKI) incidence rate was also significantly higher in the IV group than the Neb group (62.1% vs. 23.7%, p<0.001, respectively). Conclusion : The efficacy of nebulized colistin was similar with intravenous colistin for ICU patients with pneumonia caused by MDR A. baumannii or P. aeruginosa. Also, nebulized colistin showed favorable results in serum creatinine change and the AKI incidence rate.

목차

등록된 정보가 없습니다.

참고문헌 (20)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0